Oncology Biosimilars: A Primer for Clinicians

Download these slides with expert recommendations on the approval and integration of oncology biosimilars for clinical practice.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Format: Microsoft PowerPoint (.ppt)
File Size: 4.66 MB
Released: April 20, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Amgen

Related Content

On-demand Webcast with Nathan Pennell, MD, PhD, and Laura Tafe, MD, discussing biomarker testing and personalized therapy in lung cancer, from Clinical Care Options (CCO)

Nathan Pennell, MD, PhD Laura J. Tafe, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit ABIM MOC: maximum of 1.0 Medical Knowledge MOC point(s) ABPath MOC: maximum of 1.0 Lifelong Learning MOC point Released: January 15, 2021 Expired: January 14, 2022

CCO Conference Coverage of ASCO GI 2021 with downloadable slides and expert commentary of clinically relevant studies

Axel Grothey Headshot Axel Grothey, MD Manish A. Shah, MD Released: January 14, 2021

Enter characteristics of your patient with NSCLC into this online tool from Clinical Care Options to see treatment recommendations from 5 experts

Matthew Gubens, MD, MS Wade T. Iams, MD, MSCI Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS H. Jack West, MD Released: January 12, 2021

Downloadable slides with notes from pharmacist and nursing experts on maintenance avelumab, enfortumab vedotin and erdafitinib for urothelial carcinoma, from CCO

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Released: January 11, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue